Therapeutically effective 1α, 25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases
AssigneeThe Regents of the University of California
InventorsAnthony W. Norman, William H. Okamura
Life of this patent
Estimating the term…
Abstract
A method for treatment of diseases caused by deficiency or overproduction of the vitamin D3 metabolites by administering analogs of 1α,25-dihydroxyvitamin D3. These analogs are selective agonists or antagonists for the genomic and rapid nongenomic cellular responses. A pharmaceutical composition comprising 1α,25-dihydroxyvitamin D3 analog.
Claims6
A method for treatment of diseases connected with or caused by vitamin D3 deficiency by providing a subject in need of such treatment a vitamin D3 analog selected from the group consisting of the analog GE, namely, 14-epi-1α,25(OH)2D3, analog GF, namely, 14-epi-1α,25(OH)2-pre-D3, analog HJ, namely, 1α,25(OH)2-3-epi-D3, analog HQ, namely, (22S)-1α,25(OH)2-22,23-diene-D3, analog HR, namely, (22R)-1α,25(OH)2-22,23-diene-D3, analog JR, namely, 1α,25(OH)2-7,8-cis-D3, analog JS, namely, 1α,25(OH)2-5,6-trans-7,8-cis-D3, analog JV, namely, (1S,3R,6S)-1,3,25-trihydroxy-9,10-secocholesta-5(10),6,7-triene and analog JW, namely, (1S,3R,6R)-1,3,25-trihydroxy-9,10-secocholesta-5(10),6,7-triene.
Dependencies are inferred from the claim text.